Side Effects of decitabine injection: A Synthesis of Findings from 2 Studies

  1. Home
  2. Side Effects of decitabine injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of decitabine injection: A Synthesis of Findings from 2 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of decitabine injection: A Synthesis of Findings from 2 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Decitabine, a hypomethylating agent, has shown potential to modulate the toxicity and antitumor activity of immunotherapy in patients with melanoma or renal cell carcinoma. 2 Decitabine combined with cytarabine-based low dose regimen showed promising therapeutic effectiveness and safety in treating senile patients with acute myeloid leukemia. 1

Reasons for Side Effects

Side effects of decitabine are likely due to its ability to inhibit DNA methylation, which affects cell growth and differentiation. Additionally, it can activate the immune system, potentially leading to inflammatory and autoimmune reactions.

Common Side Effects

Hematologic Side Effects

Decitabine can cause myelosuppression, meaning it can suppress the production of red blood cells, white blood cells, and platelets. 2

Gastrointestinal Side Effects

Decitabine may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. 2

Skin Side Effects

Decitabine can cause skin rashes and erythema. 2

Other Side Effects

Decitabine can cause side effects such as fatigue, fever, and liver or kidney dysfunction. 2

Side Effects Management

Hematologic Side Effects

If myelosuppression occurs, treatments such as blood transfusions and growth factors may be necessary. 2

Gastrointestinal Side Effects

If nausea or vomiting occurs, treatments such as antiemetics may be necessary. 2

Skin Side Effects

If skin rashes occur, treatments such as steroid creams may be necessary. 2

Comparison Between Studies

Commonalities

Both studies involved clinical trials to assess the efficacy and safety of decitabine. 2 1

Differences

The two studies targeted different cancer types and used different methods of administering decitabine. 2 1

Points to Note Regarding Real-Life Applications

Decitabine is a promising drug for cancer treatment, but it can cause serious side effects. 2 It is important to use it safely under the guidance of a doctor. 2

Current Research Limitations

Further research is needed to determine the long-term safety and effectiveness of decitabine. 2

Future Research Directions

More research is needed to determine the optimal dosage and combination therapy for decitabine. 2 Research is also needed to identify cancer types and patients for whom decitabine is effective. 2

Conclusion

Decitabine is a promising drug for cancer treatment, but it can cause serious side effects. 2 It is important to use it safely under the guidance of a doctor. 2 Future research is expected to further clarify the safety and efficacy of decitabine. 2

Literature analysis of 2 papers
Positive Content
1
Neutral Content
1
Negative Content
0
Article Type
0
0
0
0
2
1.

[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].

Author: ZhouHong-Wei, ZhouMin-Hang, WangZhi-Hong, LiPeng-Fei, LiuMo, DUYu, YaoYi-Bing, PengChao-Jin, JingYu, SunJun-Zhong

Leukemia response rate
Survival time

Decitabine combined with or without cytarabine-based low-dose regimen showed promising results in treating geriatric acute myeloid leukemia, improving overall response rate and prolonging survival time.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Chinese

2.

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

Author: GollobJared A, SciambiCatherine J, PetersonBercedis L, RichmondTina, ThoresonMonica, MoranKelly, DressmanHolly K, JelinekJaroslav, IssaJean-Pierre J

Antitumor activity
Toxicity

This study investigates the use of 5-aza-2'-deoxycytidine (decitabine) plus high-dose interleukin 2 (IL-2) in patients with melanoma and renal cell cancer. The combination aims to modulate the toxicity and antitumor activity of immunotherapy by using a hypomethylating agent.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.